GlassScriptPhysician profile
Anthony J Langone
NPI 1841387974
$22,826.36
in general payments reported to CMS, 2019-2025
12 companies · $9,436 in 2025
The $9,436 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $13K · 2022: $13.09 · 2023: $260 · 2024: $382 · 2025: $9,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,263 · Food and Beverage: $1,704 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,262.50 |
| Food and Beverage | $1,704.15 |
| Education | $111.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $16,556.36 | 2021-2025 | Envarsus |
| Alnylam Pharmaceuticals INC. | $2,902.20 | 2021-2025 | Oxlumo, Givlaari |
| Novo Nordisk INC | $1,574.03 | 2021-2025 | Rivfloza |
| Biogen, INC. | $509.85 | 2025 | |
| Alexion Pharmaceuticals, INC. | $406.27 | 2023-2024 | Ultomiris, Soliris |
| Calliditas Therapeutics US INC. | $247.82 | 2024-2025 | Tarpeyo |
| Apellis Pharmaceuticals, INC. | $158.19 | 2025 | Empaveli |
| Otsuka America Pharmaceutical, INC. | $150.77 | 2019-2022 | |
| Genzyme Corporation | $138.15 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $99.42 | 2025 | Nulojix |
| Integra Lifesciences Corporation | $45.46 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Takeda Pharmaceuticals U.S.A., INC. | $37.84 | 2025 | Livtencity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Langone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.